Company Overview
About Alzheon
Alzheon is a clinical-stage biotechnology company founded in 2013 and headquartered in Framingham, Massachusetts. The company is focused on developing disease-modifying treatments for Alzheimer's disease, with its lead drug candidate ALZ-801 (valiltramiprosate) — an oral small molecule that targets and inhibits the formation of toxic amyloid beta oligomers, which are believed to be the primary drivers of synaptic damage and cognitive decline in Alzheimer's patients.
Business Model & Competitive Advantage
ALZ-801 is designed specifically for patients carrying the APOE4 gene variant, which significantly elevates lifetime Alzheimer's risk. Alzheon completed a Phase 2b/3 clinical trial — the APOLLOE4 study — showing statistically significant slowing of cognitive decline in APOE4/4 homozygous patients. The company is advancing toward FDA submission based on these results. Unlike the recently approved IV infusion antibody therapies (lecanemab, donanemab), ALZ-801 is an oral tablet, which could make it substantially more accessible and practical for long-term patient use.
Competitive Landscape 2025–2026
Alzheon has raised over $100M in funding from investors including Sofinnova Partners and other life sciences-focused backers. The company's strategy targets precision medicine: identifying genetically at-risk patients early and intervening with a tolerable, outpatient-friendly oral therapy. If approved, ALZ-801 would represent a differentiated entry in the Alzheimer's treatment market, competing with infusion-based amyloid therapies on the basis of convenience, tolerability, and cost of administration.
Key Differentiators
Emerging Innovator
Alzheon is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Florence Healthcare
Florence Healthcare is the dominant software platform for clinical trial site enablement, providing digital tools that connect trial sites, sponsors, and contract research organizations (CROs) to stre
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Compare Alzheon with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Alzheon? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Alzheon Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Alzheon vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →